|Table of Contents|

Expression and clinical pathological significance of Chk1 in breast carcinoma tissues

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 03
Page:
456-459
Research Field:
Publishing date:

Info

Title:
Expression and clinical pathological significance of Chk1 in breast carcinoma tissues
Author(s):
YUAN Huijun1; LIU Bin2; YU Wenqing3; SU Qinjun2; YANG Yanli2; LI Haiying1
1.Wuwei Tumor Hospital of Gansu Province,Gansu Wuwei 733000,China;2.the 940th Hospital of the Joint Logistic Support Force of the People's Liberation Army of China,Gansu Lanzhou 730050,China;3.Yongchang Town Center Health Center,Liangzhou District,Wuwei City,Gansu Wuwei 733000,China.
Keywords:
breast cancer; Chk1; immunohistochemical; prognosis
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2022.03.016
Abstract:
Objective:To detect the expression level of checkpoint kinase1(Chk1) in breast cancer tissues and explore its relationship with clinicopathological features and prognosis.Methods:From January 2012 to January 2017,115 cases of breast cancer tissue wax blocks were archived in the department of pathology in our hospital.The expression level of Chk1 was detected by immunohistochemistry.Chi-square test was used to analyze the relationship between the expression of Chk1 and clinicopathological features.Kaplan-Meier method and Log-rank test were used to analyze the survival data of patients.Results:Chk1 was widely expressed in breast cancer tissues with a positive rate of 73%.The expression level of Chk1 was correlated with the age of the patient,the clinical stage of the tumor and the expression level of p53(P＜0.05).Kaplan-Meier survival analysis showed that the expression of Chk1 was statistically significant compared with the 5-year OS of the patients(P＜0.05).There was no significant difference between the 3-year OS and PFS and 5-year PFS(P＞0.05).Conclusion:The expression of Chk1 in breast cancer tissues is related to the prognosis of patients,and patients with negative expression can obtain PFS and OS for a longer time,indicating that Chk1 is expected to become a potential target for the treatment of breast cancer.

References:

[1]BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancerstatistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
[2]郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志,2019,41(1):19-28. ZHENG RS,SUN KX,ZHANG SW,et al.Analysis on the prevalence of malignant tumors in China in 2015［J］.Chin J Oncol,2019,41(1):19-28.
[3]CHEN CH,CHU PC,LEE L,et al.Disruption of murine mp29/Syf2/Ntc31 gene results in embryonic lethality with aberrant checkpoint response［J］.PLoS One,2012,7(3):e33538．
[4]MENOLFI D,JIANG W,LEE BJ,et al.Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA［J］.Nat Commun,2018,9(1):5351.
[5]GOTO H,NATSUME T,KANEMAKI MT,et al.Chk1-mediated Cdc25A degradation as a critical mechanism for normal cell cycle progression［J］.J Cell Sci,2019,132(2):223123.
[6]CIARDO D,GOLDAR A,MARHEINEKE K.On the interplay of the DNA replication program and the intra-S phase checkpoint pathway［J］.Genes,2019,10(2):94
[7]RAKESH DESHAR,WONJIN YOO,EUN-BEE CHO,et al.RNF8 mediates NONO degradation following UV-induced DNA damage to properly terminate ATR-CHK1 checkpoint signaling ［J］.Nucleic Acids Res,2019,47(2):762-778.
[8]DE GOOIJER MC,VAN DEN TOP A,BOCKAJ I,et al.The G2 checkpoint-a node-based molecular switch［J］.FEBS Open Bio,2017,7(4):439-455.
[9]JUNG KW,LEE Y,HUH EY,et al.Rad53-and Chk1-dependent DNA damage response pathways cooperatively promote fungalpathogenesis and modulate antifungal drug suscep-tibility［J］.MBio,2019,10(1):e01726-01718.
[10]SIDI S,SANDA T,KENNEDY RD,et al.Chk1 suppresses a caspase-2apoptotic response to DNA damage that bypasses p53,Bcl-2 and caspase-3［J］.Cell,2008,133:864-877.
[11]MA Y,CUI D,XIONG X,et al.SCFβ-TrCP ubiquitinates CHK1 in an AMPK-dependent manner in response to glucosedeprivation［J］.Mol Oncol,2019,13(2):307-321.
[12]CHUNG SW,KIM GC,KWEON S,et al.Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breastcancer treatment［J］.Biomaterials,2018,182:35-43.
[13]WARREN NJH,EASTMAN A.Inhibition of checkpoint kinase 1 following gemcitabinemedia-ted S phase arrest results in CDC7-and CDK2-dependent replication catastrophe［J］.J Biol Chem,2019,294(6):1763-1778.
[14]LOWERY CD,DOWLESS M,RENSCHLER M,et al.Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of pre-clinical pediatric tumor models［J］.Clin Cancer Res,2018,25(7):2278-2728.
[15]许良中,杨文涛.免疫组织化学反应结果的判断标准［J］.中国癌症杂志,1996(4):229-231. XU LZ,YANG WT.Criteria for the outcome of immunohistochemical reactions［J］.China Oncology,1996(4):229-231.
[16]SALGADO R,DENKERT C,DEMARIA S,et al.The evaluation of tumor-infiltrating lymphocytes(TILs) in breast cancer:recommendations by an International TILs working group 2014［J］.Ann Oncol,2015,26(2):259-271.
[17]CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
[18]霍正浩.抑癌基因研究进展［J］.宁夏医学院学报,1998,20(4):89-91. HUO ZH.Advances in the study of tumor suppressor genes［J］.Journal of Ningxia Medical College,1998,20(4):89-91.
[19]YUAN HJ ,LIU B,YANG YL,et al.Advances in the study of Wee1 protein kinase［J］.Chin J of Oncol Prev and Treat,2018,10(1):61-64.
[20]袁会军,张秋菊,刘斌,等.Chk1蛋白激酶及其抑制剂的研究进展［J］.现代肿瘤医学,2018,26(17):2797-2800. YUAN HJ,ZHANG QJ,LIU B,et al.Advances in the study of Chk1 protein kinase and its inhibitors［J］.Modern Oncology,2018,26(17):2797-2800.

Memo

Memo:
-
Last Update: 2021-12-31